Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its late-stage candidate for metabolic dysfunction-associated steatohepatitis (MASH). The $14.50-per-share deal ...
The L.A. Report is a breakdown of the day's top news from Southern California, featuring the award-winning reporting of LAist 89.3 FM – L.A.'s number one NPR station. Hosted by Austin Cross in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results